Abstract
Hypopituitarism is the deficiency in varying degrees of one or multiple pituitary hormones. In this chapter, deficiency of growth hormone (GH) will be discussed, while other hormonal deficiencies are presented elsewhere in this book. To understand GH deficiency (GHD), the mechanisms of GH production and its secretion are first presented. There are multiple etiologies of GHD, and an ever-increasing number of genetic causes have been uncovered. However, the ability to make the diagnosis of GHD still remains difficult, and interpretation of laboratory studies remains controversial.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Asa SL, et al. The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab. 1996;81(6):2165–70.
Dutour A. A new step understood in the cascade of tissue-specific regulators orchestrating pituitary lineage determination: the Prophet of Pit-1 (Prop-1). Eur J Endocrinol. 1997;137(6):616–7.
Rosenfeld RG. Disorders of growth hormone and insulin-like growth factor secretion and action. In: Sperling MA, editor. Pediatric endocrinology. Philadelphia: W.B. Saunders; 1996. p. 117–69.
Reichlin S. Neuroendocrinology. In: Wilson JD, Foster DW, editors. Williams textbook of endocrinology. Philadelphia: W.B. Saunders; 1991. p. 1079–138.
Gorczyca W, Hardy J. Arterial supply of the human anterior pituitary gland. Neurosurgery. 1987;20(3):369–78.
Blethen SL. Hypopituitarism. In: Lifshitz F, editor. Pediatric endocrinology. New York: Marcel Dekker Inc; 1996. p. 19–31.
Backeljauw PHV. Growth hormone physiology. In: Cohen LE, editor. Growth hormone deficiency, physiology and clinical management. Cham: Springer International Publishing; 2016. p. 7–20.
DeNoto FM, Moore DD, Goodman HM. Human growth hormone DNA sequence and mRNA structure: possible alternative splicing. Nucl Acids Res. 1981;9(15):3719–30.
Cooke NE, et al. Human growth hormone gene and the highly homologous growth hormone variant gene display different splicing patterns. J Clin Invest. 1988;82(1):270–5.
Baumann G, et al. A specific growth hormone-binding protein in human plasma: initial characterization. J Clin Endocrinol Metab. 1986;62(1):134–41.
Chen EY, et al. The human growth hormone locus: nucleotide sequence, biology, and evolution. Genomics. 1989;4(4):479–97.
Nielsen PV, Pedersen H, Kampmann EM. Absence of human placental lactogen in an otherwise uneventful pregnancy. Am J Obstet Gynecol. 1979;135(3):322–6.
Frankenne F, et al. Identification of placental human growth hormone as the growth hormone-V gene expression product. J Clin Endocrinol Metab. 1990;71(1):15–8.
de Zegher F, et al. Perinatal growth hormone (GH) physiology: effect of GH-releasing factor on maternal and fetal secretion of pituitary and placental GH. J Clin Endocrinol Metab. 1990;71(2):520–2.
Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734–44.
Chen C, Clarke IJ. Modulation of Ca2+ influx in the ovine somatotroph by growth hormone-releasing factor. Am J Phys. 1995;268(2 Pt 1):E204–12.
Mayo KE, et al. Growth hormone-releasing hormone: synthesis and signaling. Recent Prog Horm Res. 1995;50:35–73.
Barinaga M, et al. Transcriptional regulation of growth hormone gene expression by growth hormone-releasing factor. Nature. 1983;306(5938):84–5.
Bilezikjian LM, Vale WW. Stimulation of adenosine 3′,5′-monophosphate production by growth hormone-releasing factor and its inhibition by somatostatin in anterior pituitary cells in vitro. Endocrinology. 1983;113(5):1726–31.
Cohen LE, et al. CREB-independent regulation by CBP is a novel mechanism of human growth hormone gene expression. J Clin Invest. 1999;104(8):1123–30.
Law SF, Manning D, Reisine T. Identification of the subunits of GTP-binding proteins coupled to somatostatin receptors. J Biol Chem. 1991;266(27):17885–97.
Law SF, et al. Gi alpha 3 and G(o) alpha selectively associate with the cloned somatostatin receptor subtype SSTR2. J Biol Chem. 1993;268(15):10721–7.
Fujii Y, et al. Somatostatin receptor subtype SSTR2 mediates the inhibition of high voltage activated calcium channels by somatostatin and its analogue SMS. FEBS Lett. 1996;355:117–20.
Tannenbaum GS, Ling N. Evidence for autoregulation of growth hormone secretion via the central nervous system. Endocrinology. 1980;115:1952–7.
Mauras N, et al. Augmentation of growth hormone secretion during puberty: evidence for a pulse amplitude-modulated phenomenon. J Clin Endocrinol Metab. 1987;64(3):596–601.
Rose SR, et al. Spontaneous growth hormone secretion increases during puberty in normal girls and boys. J Clin Endocrinol Metab. 1991;73:428–35.
Martha PM Jr, et al. Endogenous growth hormone secretion and clearance rates in normal boys, as determined by deconvolution analysis: relationship to age, pubertal status, and body mass. J Clin Endocrinol Metab. 1992;74(2):336–44.
Dudl RJ, et al. Effect of age on growth hormone secretion in man. J Clin Endocrinol Metab. 1973;37(1):11–6.
Rudman D, et al. Impaired growth hormone secretion in the adult population: relation to age and adiposity. J Clin Invest. 1981;67(5):1361–9.
Leung AMBGA. The influence of thyroid hormone on growth hormone secretion and action. In: Cohen LE, editor. Growth hormone deficiency, physiology and clinical management. Cham: Springer International Publishing; 2016. p. 29–46.
Stanley TL. Obesity and growth hormone secretion. In: Cohen LE, editor. Growth hormone deficiency, physiology and clinical management. Cham: Springer International Publishing; 2016. p. 63–77.
Baskaran CMM. Undernutrition, inflammation and catabolic illness, and growth hormone secretion. In: Cohen LE, editor. Growth hormone deficiency, physiology and clinical management. Cham: Springer International Publishing; 2016. p. 47–61.
Korbonits M, Grossman AB. Growth hormone-releasing peptide and its analogues Novel stimuli to growth hormone release. Trends Endocrinol Metab. 1995;6(2):43–9.
Smith RG, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997;18(5):621–45.
Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974–7.
Kojima M, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–60.
Hataya Y, et al. A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J Clin Endocrinol Metab. 2001;86(9):4552.
Date Y, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology. 2000;141(11):4255–61.
Nakazato M, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001;409(6817):194–8.
Higgins SC, Gueorguiev M, Korbonits M. Ghrelin, the peripheral hunger hormone. Ann Med. 2007;39(2):116–36.
Baumann G. Growth hormone binding protein 2001. J Pediatr Endocrinol Metab. 2001;14(4):355–75.
Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A. 1990;87(18):6934–8.
Godowski PJ, et al. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. Proc Natl Acad Sci U S A. 1989;86(20):8083–7.
Gent J, et al. Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Proc Natl Acad Sci U S A. 2002;99(15):9858–63.
Brown RJ, et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol. 2005;12(9):814–21.
Campbell GS, Christian LJ, Carter-Su C. Evidence for involvement of the growth hormone receptor-associated tyrosine kinase in actions of growth hormone. J Biol Chem. 1993;268(10):7427–34.
Argetsinger LS, et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell. 1993;74(2):237–44.
Silva CM, Weber MJ, Thorner MO. Stimulation of tyrosine phosphorylation in human cells by activation of the human growth hormone receptor. Endocrinology. 1995;132:101–8.
Silva CM, Lu H, Day RN. Characterization and cloning of STAT5 from IM-9 cells and its activation by growth hormone. Mol Endocrinol. 1996;10(5):508–18.
Smit LS, et al. The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3, and 5 by GH. Mol Endocrinol. 1996;10(5):519–33.
Salmon WD Jr, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med. 1957;49(6):825–36.
Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev. 1989;10(1):68–91.
Ohlsson C, et al. Growth hormone and bone. Endocr Rev. 1998;19(1):55–79.
Isaksson OG, Jansson JO, Gause IA. Growth hormone stimulates longitudinal bone growth directly. Science. 1982;216(4551):1237–9.
Maor G, Hochberg Z, Silbermann M. Growth hormone stimulates the growth of mouse neonatal condylar cartilage in vitro. Acta Endocrinol. 1989;120(4):526–32.
Maor G, et al. Human growth hormone enhances chondrogenesis and osteogenesis in a tissue culture system of chondroprogenitor cells. Endocrinology. 1989;125(3):1239–45.
Isgaard J, et al. Regulation of insulin-like growth factor messenger ribonucleic acid in rat growth plate by growth hormone. Endocrinology. 1988;122(4):1515–20.
Gluckman PD, et al. Studies of insulin-like growth factor I and II by specific radioligand assays in umbilical cord blood. Clin Endocrinol. 1983;19:405.
Bennett A, et al. Levels of insulin-like growth factors I and II in human cord blood. J Clin Endocrinol Metab. 1983;57(3):609–12.
Luna AM, et al. Somatomedins in adolescence: a cross-sectional study of the effect of puberty on plasma insulin-like growth factor I and II levels. J Clin Endocrinol Metab. 1983;57(2):268–71.
Cara JF, Rosenfield RL, Furlanetto RW. A longitudinal study of the relationship of plasma somatomedin-C concentration to the pubertal growth spurt. Am J Dis Child. 1987;141(5):562–4.
Johanson AJ, Blizzard RM. Low somatomedin-C levels in older men rise in response to growth hormone administration. Johns Hopkins Med J. 1981;149(3):115–7.
Elgin RG, Busby WH Jr, Clemmons DR. An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. Proc Natl Acad Sci U S A. 1987;84(10):3254–8.
Lamson G, Giudice LC, Rosenfeld RG. Insulin-like growth factor binding proteins: structural and molecular relationships. Growth Factors. 1991;5(1):19–28.
Kelley KM, et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol. 1996;28(6):619–37.
Chernausek SD, Jacobs S, Van Wyk JJ. Structural similarities between human receptors for somatomedin C and insulin: analysis by affinity labeling. Biochemistry. 1981;20(26):7345–50.
Massague J, Czech MP. The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J Biol Chem. 1982;257(9):5038–45.
Oh Y, et al. Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs. Endocrinology. 1993;132(3):1337–44.
Rona RJ, Tanner JM. Aetiology of idiopathic growth hormone deficiency in England and Wales. Arch Dis Child. 1977;52:197–208.
Vimpani GV, et al. Prevalence of severe growth hormone deficiency. Br Med J. 1977;2(6084):427–30.
Gaylinn BD, et al. The mutant growth hormone-releasing hormone (GHRH) receptor of the little mouse does not bind GHRH. Endocrinology. 1999;140(11):5066–74.
Godfrey P, et al. GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function. Nat Genet. 1993;4(3):227–32.
Lin SC, et al. Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature. 1993;364(6434):208–13.
Wajnrajch MP, et al. Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse. Nat Genet. 1996;12(1):88–90.
Maheshwari HG, et al. Phenotype and genetic analysis of a syndrome caused by an inactivating mutation in the growth hormone-releasing hormone receptor: Dwarfism of Sindh. J Clin Endocrinol Metab. 1998;83(11):4065–74.
Wit JMLMBG. Growth hormone-releasing hormone receptor and growth hormone gene abnormalities. In: Cohen LE, editor. Growth hormone deficiency, physiology and clinical management. Cham: Springer International Publishing; 2016. p. 149–75.
Dasen JS, et al. Temporal regulation of a paired-like homeodomain repressor/TLE corepressor complex and a related activator is required for pituitary organogenesis. Genes Dev. 2001;15(23):3193–207.
Kelberman D, et al. Genetic regulation of pituitary gland development in human and mouse. Endocr Rev. 2009;30(7):790–829.
Scully KM, Rosenfeld MG. Pituitary development: regulatory codes in mammalian organogenesis. Science. 2002;295(5563):2231–5.
Wang Y, Martin JF, Bai CB. Direct and indirect requirements of Shh/Gli signaling in early pituitary development. Dev Biol. 2010;348(2):199–209.
Park HL, et al. Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation. Development. 2000;127(8):1593–605.
Cohen LE. GLI2 mutations as a cause of hypopituitarism. Pediatr Endocrinol Rev. 2012;9(4):706–9.
Dattani MT, et al. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet. 1998;19(2):125–33.
Hermesz E, Mackem S, Mahon KA. Rpx: a novel anterior-restricted homeobox gene progressively activated in the prechordal plate, anterior neural plate and Rathke’s pouch of the mouse embryo. Development. 1996;122(1):41–52.
Cohen LE. Genetic disorders of the pituitary. Curr Opin Endocrinol Diabetes Obes. 2012;19(1):33–9.
Thomas PQ, et al. Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia. Hum Mol Genet. 2001;10(1):39–45.
McNay DE, et al. HESX1 mutations are an uncommon cause of septooptic dysplasia and hypopituitarism. J Clin Endocrinol Metab. 2007;92(2):691–7.
Fang Q, et al. HESX1 mutations in patients with congenital hypopituitarism: variable phenotypes with the same genotype. Clin Endocrinol. 2016;85(3):408–14.
Lamonerie T, et al. Ptx1, a bicoid-related homeo box transcription factor involved in transcription of the pro-opiomelanocortin gene. Genes Dev. 1996;10(10):1284–95.
Shimada A, et al. A novel mutation in OTX2 causes combined pituitary hormone deficiency, bilateral microphthalmia, and agenesis of the left internal carotid artery. Horm Res Paediatr. 2016;86(1):62–9.
Lonero A, et al. A novel OTX2 gene frameshift mutation in a child with microphthalmia, ectopic pituitary and growth hormone deficiency. J Pediatr Endocrinol Metab. 2016;29(5):603–5.
Tajima T, Ishizu K, Nakamura A. Molecular and clinical findings in patients with LHX4 and OTX2 mutations. Clin Pediatr Endocrinol. 2013;22(2):15–23.
Gorbenko Del Blanco D, et al. A novel OTX2 mutation in a patient with combined pituitary hormone deficiency, pituitary malformation, and an underdeveloped left optic nerve. Eur J Endocrinol. 2012;167(3):441–52.
Diaczok D, et al. A novel dominant negative mutation of OTX2 associated with combined pituitary hormone deficiency. J Clin Endocrinol Metab. 2008;93(11):4351–9.
Dateki S, et al. OTX2 mutation in a patient with anophthalmia, short stature, and partial growth hormone deficiency: functional studies using the IRBP, HESX1, and POU1F1 promoters. J Clin Endocrinol Metab. 2008;93(10):3697–702.
Tajima T, et al. OTX2 loss of function mutation causes anophthalmia and combined pituitary hormone deficiency with a small anterior and ectopic posterior pituitary. J Clin Endocrinol Metab. 2009;94(1):314–9.
Dateki S, et al. Heterozygous orthodenticle homeobox 2 mutations are associated with variable pituitary phenotype. J Clin Endocrinol Metab. 2010;95(2):756–64.
Henderson RH, et al. A rare de novo nonsense mutation in OTX2 causes early onset retinal dystrophy and pituitary dysfunction. Mol Vis. 2009;15:2442–7.
Suh H, et al. Pitx2 is required at multiple stages of pituitary organogenesis: pituitary primordium formation and cell specification. Development. 2002;129(2):329–37.
Lin CR, et al. Pitx2 regulates lung asymmetry, cardiac positioning and pituitary and tooth morphogenesis. Nature. 1999;401(6750):279–82.
Gage PJ, Suh H, Camper SA. Dosage requirement of Pitx2 for development of multiple organs. Development. 1999;126(20):4643–51.
Semina EV, Reiter RS, Murray JC. Isolation of a new homeobox gene belonging to the Pitx/Rieg family: expression during lens development and mapping to the aphakia region on mouse chromosome 19. Hum Mol Genet. 1997;6(12):2109–16.
Amendt BA, et al. The molecular basis of Rieger syndrome. Analysis of Pitx2 homeodomain protein activities. J Biol Chem. 1998;273(32):20066–72.
Amendt BA, Semina EV, Alward WL. Rieger syndrome: a clinical, molecular, and biochemical analysis. Cell Mol Life Sci. 2000;57(11):1652–66.
Zhadanov AB, et al. Expression pattern of the murine LIM class homeobox gene Lhx3 in subsets of neural and neuroendocrine tissues. Dev Dyn. 1995;202(4):354–64.
Sheng HZ, et al. Specification of pituitary cell lineages by the LIM homeobox gene Lhx3. Science. 1996;272(5264):1004–7.
Kristrom B, et al. A novel mutation in the LIM homeobox 3 gene is responsible for combined pituitary hormone deficiency, hearing impairment, and vertebral malformations. J Clin Endocrinol Metab. 2009;94(4):1154–61.
Rajab A, et al. Novel mutations in LHX3 are associated with hypopituitarism and sensorineural hearing loss. Hum Mol Genet. 2008;17(14):2150–9.
Pfaeffle RW, et al. Four novel mutations of the LHX3 gene cause combined pituitary hormone deficiencies with or without limited neck rotation. J Clin Endocrinol Metab. 2007;92(5):1909–19.
Sobrier ML, et al. Symptomatic heterozygotes and prenatal diagnoses in a nonconsanguineous family with syndromic combined pituitary hormone deficiency resulting from two novel LHX3 mutations. J Clin Endocrinol Metab. 2012;97(3):E503–9.
Castinetti FBT. Combined pituitary growth hormone deficiency. In: Cohen LE, editor. Growth hormone deficiency, physiology and clinical management. Cham: Springer International Publishing; 2016. p. 177–94.
Castinetti F, et al. MECHANISMS IN ENDOCRINOLOGY: an update in the genetic aetiologies of combined pituitary hormone deficiency. Eur J Endocrinol. 2016;174(6):R239–47.
Kelberman D, et al. Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. J Clin Invest. 2006;116(9):2442–55.
Macchiaroli A, et al. A novel heterozygous SOX2 mutation causing congenital bilateral anophthalmia, hypogonadotropic hypogonadism and growth hormone deficiency. Gene. 2014;534(2):282–5.
Raivio T, et al. Genetic overlap in Kallmann syndrome, combined pituitary hormone deficiency, and septo-optic dysplasia. J Clin Endocrinol Metab. 2012;97(4):E694–9.
Fluck C, et al. Phenotypic variability in familial combined pituitary hormone deficiency caused by a PROP1 gene mutation resulting in the substitution of Arg-->Cys at codon 120 (R120C). J Clin Endocrinol Metab. 1998;83(10):3727–34.
Perez Millan MI, et al. PROP1 triggers epithelial-mesenchymal transition-like process in pituitary stem cells. Elife. 2016;5:pii: e14470.
Vieira TC, da Silva MR, Abucham J. The natural history of the R120C PROP1 mutation reveals a wide phenotypic variability in two untreated adult brothers with combined pituitary hormone deficiency. Endocrine. 2006;30(3):365–9.
Lebl J, et al. Auxological and endocrine phenotype in a population-based cohort of patients with PROP1 gene defects. Eur J Endocrinol. 2005;153(3):389–96.
Bottner A, et al. PROP1 mutations cause progressive deterioration of anterior pituitary function including adrenal insufficiency: a longitudinal analysis. J Clin Endocrinol Metab. 2004;89(10):5256–65.
Pavel ME, et al. Long-term follow-up of childhood-onset hypopituitarism in patients with the PROP-1 gene mutation. Horm Res. 2003;60(4):168–73.
Deladoey J, et al. “Hot spot” in the PROP1 gene responsible for combined pituitary hormone deficiency. J Clin Endocrinol Metab. 1999;84(5):1645–50.
Himes AD, Raetzman LT. Premature differentiation and aberrant movement of pituitary cells lacking both Hes1 and Prop1. Dev Biol. 2009;325(1):151–61.
Fofanova O, et al. Compound heterozygous deletion of the PROP-1 gene in children with combined pituitary hormone deficiency. J Clin Endocrinol Metab. 1998;83(7):2601–4.
Fofanova OV, et al. A mutational hot spot in the Prop-1 gene in Russian children with combined pituitary hormone deficiency. Pituitary. 1998;1(1):45–9.
Cogan JD, et al. The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency. J Clin Endocrinol Metab. 1998;83(9):3346–9.
Bodner M, et al. The pituitary-specific transcription factor GHF-1 is a homeobox-containing protein. Cell. 1988;55(3):505–18.
Simmons DM, et al. Pituitary cell phenotypes involve cell-specific Pit-1 mRNA translation and synergistic interactions with other classes of transcription factors. Genes Dev. 1990;4(5):695–711.
Tatsumi K, et al. Cretinism with combined hormone deficiency caused by a mutation in the PIT1 gene. Nat Genet. 1992;1(1):56–8.
Radovick S, et al. A mutation in the POU-homeodomain of Pit-1 responsible for combined pituitary hormone deficiency. Science. 1992;257(5073):1115–8.
Pfaffle RW, et al. Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia. Science. 1992;257(5073):1118–21.
Ohta K, et al. Mutations in the Pit-1 gene in children with combined pituitary hormone deficiency. Biochem Biophys Res Commun. 1992;189(2):851–5.
Cohen LE, et al. A “hot spot” in the Pit-1 gene responsible for combined pituitary hormone deficiency: clinical and molecular correlates. J Clin Endocrinol Metab. 1995;80(2):679–84.
Okamoto N, et al. Monoallelic expression of normal mRNA in the PIT1 mutation heterozygotes with normal phenotype and biallelic expression in the abnormal phenotype. Hum Mol Genet. 1994;3(9):1565–8.
de Zegher F, et al. The prenatal role of thyroid hormone evidenced by fetomaternal Pit-1 deficiency. J Clin Endocrinol Metab. 1995;80(11):3127–30.
Holl RW, et al. Combined pituitary deficiencies of growth hormone, thyroid stimulating hormone and prolactin due to Pit-1 gene mutation: a case report. Eur J Pediatr. 1997;156(11):835–7.
Aarskog D, et al. Pituitary dwarfism in the R271W Pit-1 gene mutation. Eur J Pediatr. 1997;156(11):829–34.
Arnhold IJ, et al. Clinical and molecular characterization of a Brazilian patient with Pit-1 deficiency. J Pediatr Endocrinol Metab. 1998;11(5):623–30.
Ward L, et al. Severe congenital hypopituitarism with low prolactin levels and age-dependent anterior pituitary hypoplasia: a clue to a PIT-1 mutation. J Pediatr. 1998;132(6):1036–8.
Jacobson EM, et al. Structure of Pit-1 POU domain bound to DNA as a dimer: unexpected arrangement and flexibility. Genes Dev. 1997;11(2):198–212.
Cohen LE, et al. Defective retinoic acid regulation of the Pit-1 gene enhancer: a novel mechanism of combined pituitary hormone deficiency. Mol Endocrinol. 1999;13(3):476–84.
Romero CJ, Nesi-Franca S, Radovick S. The molecular basis of hypopituitarism. Trends Endocrinol Metab. 2009;20(10):506–16.
Illig R, Prader A, Zachmann M. Hereditary prenatal growth hormone deficiency with increased tendency to growth hormone antibody formation (A-type of isolated growth hormone deficiency). Acta Paediatr Scandinavica. 1971;60:607.
Phillips JA, Cogan JD. Molecular basis of familial human growth hormone deficiency. J Clin Endocrinol Metab. 1994;78:11–6.
Braga S, et al. Familial growth hormone deficiency resulting from a 7.6 kb deletion within the growth hormone gene cluster. Am J Med Genet. 1986;25(3):443–52.
Perez Jurado LA, Argente J. Molecular basis of familial growth hormone deficiency. Horm Res. 1994;42(4–5):189–97.
Madeira JL, et al. A homozygous point mutation in the GH1 promoter (c.-223C>T) leads to reduced GH1 expression in siblings with isolated GH deficiency (IGHD). Eur J Endocrinol. 2016;175(2):K7–K15.
Prader A, et al. Long-term treatment with human growth hormone (Raben) in small doses. Evaluation of 18 hypopituitary patients. Helv Paediatr Acta. 1967;22(5):423–40.
Phillips JA. Inherited defects in growth hormone synthesis and action. In: Scriver CR, et al., editors. Metabolic basis of inherited disease. St. Louis: McGraw Hill; 1995. p. 3023–44.
Mullis PE, et al. Isolated autosomal dominant growth hormone deficiency: an evolving pituitary deficit? A multicenter follow-up study. J Clin Endocrinol Metab. 2005;90(4):2089–96.
Binder G, Ranke MB. Screening for growth hormone (GH) gene splice-site mutations in sporadic cases with severe isolated GH deficiency using ectopic transcript analysis. J Clin Endocrinol Metab. 1995;80(4):1247–52.
Cogan JD, et al. Familial growth hormone deficiency: a model of dominant and recessive mutations affecting a monomeric protein. J Clin Endocrinol Metab. 1994;79(5):1261–5.
Cogan JD, et al. Heterogeneous growth hormone (GH) gene mutations in familial GH deficiency. J Clin Endocrinol Metab. 1993;76(5):1224–8.
Duquesnoy P, et al. A frameshift mutation causing isolated growth hormone deficiency type IA. Am J Hum Genet. 1990;47:A110.
Igarashi Y, et al. A new type of inherited growth hormone deficiency: a compound heterozygote of a 6.7 kb deletion, including the GH-1 gene, and two base deletion deletion in the third exon of the GH-1 gene. Pediatr Res. 1993;33:S35.
Lopez-Bermejo A, Buckway CK, Rosenfeld RG. Genetic defects of the growth hormone-insulin-like growth factor axis. Trends Endocrinol Metab. 2000;11(2):39–49.
Procter AM, Phillips JA 3rd, Cooper DN. The molecular genetics of growth hormone deficiency. Hum Genet. 1998;103(3):255–72.
Cogan JD, et al. A recurring dominant negative mutation causes autosomal dominant growth hormone deficiency – a clinical research center study. J Clin Endocrinol Metab. 1995;80(12):3591–5.
Kamijo T, et al. An identical mutation in GH 1 gene associated with IGHD in two sporadic Japanese patients. Horm Res. 1997;48(suppl 2):92.
Saitoh H, et al. A Japanese family with autosomal dominant growth hormone deficiency. Eur J Pediatr. 1999;158(8):624–7.
Fleisher TA, et al. X-linked hypogammaglobulinemia and isolated growth hormone deficiency. N Engl J Med. 1980;302(26):1429–34.
Conley ME, et al. Molecular analysis of X-linked agammaglobulinemia with growth hormone deficiency. J Pediatr. 1991;119(3):392–7.
Takahashi Y, et al. Brief report: short stature caused by a mutant growth hormone. N Engl J Med. 1996;334(7):432–6.
Takahashi Y, et al. Biologically inactive growth hormone caused by an amino acid substitution. J Clin Invest. 1997;100(5):1159–65.
Hwa V, et al. Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b. J Clin Endocrinol Metab. 2005;90(7):4260–6.
Kofoed EM, et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med. 2003;349(12):1139–47.
Fang P, et al. A mutant signal transducer and activator of transcription 5b, associated with growth hormone insensitivity and insulin-like growth factor-I deficiency, cannot function as a signal transducer or transcription factor. J Clin Endocrinol Metab. 2006;91(4):1526–34.
Chia DJ, et al. Aberrant folding of a mutant Stat5b causes growth hormone insensitivity and proteasomal dysfunction. J Biol Chem. 2006;281(10):6552–8.
Laron A, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone. A new inborn error of metabolism? Israel J Med Science. 1966;2:152–5.
Amselem S, et al. Laron dwarfism and mutations of the growth hormone-receptor gene. N Engl J Med. 1989;321(15):989–95.
Amselem S, et al. Recurrent nonsense mutations in the growth hormone receptor from patients with Laron dwarfism. J Clin Invest. 1991;87(3):1098–102.
Berg MA, et al. Diverse growth hormone receptor gene mutations in Laron syndrome. Am J Hum Genet. 1993;52(5):998–1005.
Berg MA, et al. Mutation creating a new splice site in the growth hormone receptor genes of 37 Ecuadorean patients with Laron syndrome. Hum Mutat. 1992;1(1):24–32.
Kaji H, et al. Novel compound heterozygous mutations of growth hormone (GH) receptor gene in a patient with GH insensitivity syndrome. J Clin Endocrinol Metab. 1997;82(11):3705–9.
Walker JL, et al. A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-I and luteinizing hormone-releasing hormone analogue. J Clin Endocrinol Metab. 1998;83(7):2554–61.
Woods KA, et al. A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein. J Clin Endocrinol Metab. 1996;81(5):1686–90.
Ayling RM, et al. A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat Genet. 1997;16(1):13–4.
Goddard AD, et al. Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. N Engl J Med. 1995;333(17):1093–8.
Iida K, et al. Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain. J Clin Endocrinol Metab. 1998;83(2):531–7.
Baumann G, Shaw MA, Winter RJ. Absence of the plasma growth hormone-binding protein in Laron-type dwarfism. J Clin Endocrinol Metab. 1987;65(4):814–6.
Backeljauw PF, Underwood LE. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome – a clinical research center study. GHIS Collaborative Group. J Clin Endocrinol Metab. 1996;81(9):3312–7.
Laron Z, Anin S, Klinger B. Long-term IGF-1 treatment of children with Laron syndrome. Lessons fro Laron syndrome 1966–1992. Pediatr Adolesc Endocrinol. 1993;24:226–36.
Woods KA, et al. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med. 1996;335(18):1363–7.
Bowcock A, Sartorelli V. Polymorphism and mapping of the IGF1 gene, and absence of association with stature among African Pygmies. Hum Genet. 1990;85(3):349–54.
Geffner ME, et al. Insulin-like growth factor-I unresponsiveness in an Efe Pygmy. Biochem Biophys Res Commun. 1993;193(3):1216–23.
Geffner ME, et al. Insulin-like growth factor I resistance in immortalized T cell lines from African Efe Pygmies. J Clin Endocrinol Metab. 1995;80(12):3732–8.
Bozzola M, et al. The shortness of Pygmies is associated with severe under-expression of the growth hormone receptor. Mol Genet Metab. 2009;98(3):310–3.
Inagaki K, et al. A familial insulin-like growth factor-I receptor mutant leads to short stature: clinical and biochemical characterization. J Clin Endocrinol Metab. 2007;92(4):1542–8.
Raile K, et al. Clinical and functional characteristics of the human Arg59Ter insulin-like growth factor i receptor (IGF1R) mutation: implications for a gene dosage effect of the human IGF1R. J Clin Endocrinol Metab. 2006;91(6):2264–71.
Walenkamp MJ, et al. A variable degree of intrauterine and postnatal growth retardation in a family with a missense mutation in the insulin-like growth factor I receptor. J Clin Endocrinol Metab. 2006;91(8):3062–70.
Kawashima Y, et al. Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation. J Clin Endocrinol Metab. 2005;90(8):4679–87.
Abuzzahab MJ, et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med. 2003;349(23):2211–22.
Roback EW, et al. An infant with deletion of the distal long arm of chromosome 15 (q26.1----qter) and loss of insulin-like growth factor 1 receptor gene. Am J Med Genet. 1991;38(1):74–9.
Bierich JR, et al. Pseudopituitary dwarfism due to resistance to somatomedin: a new syndrome. Eur J Pediatr. 1984;142(3):186–8.
Heath-Monnig E, et al. Measurement of insulin-like growth factor I (IGF-I) responsiveness of fibroblasts of children with short stature: identification of a patient with IGF-I resistance. J Clin Endocrinol Metab. 1987;64(3):501–7.
Lanes R, et al. Dwarfism associated with normal serum growth hormone and increased bioassayable, receptorassayable, and immunoassayable somatomedin. J Clin Endocrinol Metab. 1980;50(3):485–8.
Barreca T, et al. Evaluation of anterior pituitary function in patients with posttraumatic diabetes insipidus. J Clin Endocrinol Metab. 1980;51(6):1279–82.
Yamanaka C, et al. Acquired growth hormone deficiency due to pituitary stalk transection after head trauma in childhood. Eur J Pediatr. 1993;152(2):99–101.
Craft WH, Underwoood LE, Van Wyk JJ. High incidence of perinatal insult in children with idiopathic hypopituitarism. J Pediatr. 1980;96(3 Pt 1):397–402.
Cruikshank DP. Breech presentation. Clin Obstet Gynecol. 1986;29(2):255–63.
Dunger DB, et al. The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis. N Engl J Med. 1989;321(17):1157–62.
Tien RD, et al. Thickened pituitary stalk on MR images in patients with diabetes insipidus and Langerhans cell histiocytosis. AJNR Am J Neuroradiol. 1990;11(4):703–8.
O’Sullivan RM, et al. Langerhans cell histiocytosis of hypothalamus and optic chiasm: CT and MR studies. J Comput Assist Tomogr. 1991;15(1):52–5.
Freda PU, et al. Hypothalamic-pituitary sarcoidosis. Trends Endocrinol Metab. 1992;2:321–5.
Bevan JS, et al. Reversible adrenocorticotropin deficiency due to probable autoimmune hypophysitis in a woman with postpartum thyroiditis. J Clin Endocrinol Metab. 1992;74(3):548–52.
Duranteau L, et al. Non-responsiveness of serum gonadotropins and testosterone to pulsatile GnRH in hemochromatosis suggesting a pituitary defect. Acta Endocrinol. 1993;128(4):351–4.
Oerter KE, et al. Multiple hormone deficiencies in children with hemochromatosis. J Clin Endocrinol Metab. 1993;76(2):357–61.
Pollack IF. Brain tumors in children. N Engl J Med. 1994;331(22):1500–7.
Rappaport R, Brauner R. Growth and endocrine disorders secondary to cranial irradiation. Pediatr Res. 1989;25(6):561–7.
Cohen LE. Endocrine late effects of cancer treatment. Endocrinol Metab Clin N Am. 2005;34(3):769–89. xi.
Darzy KH, et al. Cranial irradiation and growth hormone neurosecretory dysfunction: a critical appraisal. J Clin Endocrinol Metab. 2007;92(5):1666–72.
Clayton PE, Shalet SM. Dose dependency of time of onset of radiation-induced growth hormone deficiency. J Pediatr. 1991;118(2):226–8.
Shalet SM. Growth and endocrine sequelae following the treatment of childhood cancer. In: Brook CGD, editor. Clinical paediatric endocrinology. Oxford: Blackwell Science Ltd; 1995. p. 383–96.
Shalet SM, et al. Effect of spinal irradiation on growth. Arch Dis Child. 1987;62(5):461–4.
Shulman DI. Growth hormone therapy: an update. Contemp Pediatr. 1998;15(8):95–100.
Gluckman PD, et al. Congenital idiopathic growth hormone deficiency associated with prenatal and early postnatal growth failure. The International Board of the Kabi Pharmacia International Growth Study. J Pediatr. 1992;121(6):920–3.
Wabitsch M, Heinze E. Body fat in GH-deficient children and the effect of treatment. Horm Res. 1993;40(1–3):5–9.
Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000;85(11):3990–3.
Adan L, Souberbielle JC, Brauner R. Diagnostic markers of permanent idiopathic growth hormone deficiency. J Clin Endocrinol Metab. 1994;78(2):353–8.
Ranke MB, et al. Significance of basal IGF-I, IGFBP-3 and IGFBP-2 measurements in the diagnostics of short stature in children. Horm Res. 2000;54(2):60–8.
Juul A, Skakkebaek NE. Prediction of the outcome of growth hormone provocative testing in short children by measurement of serum levels of insulin-like growth factor I and insulin-like growth factor binding protein 3. J Pediatr. 1997;130(2):197–204.
Tillmann V, et al. Biochemical tests in the diagnosis of childhood growth hormone deficiency. J Clin Endocrinol Metab. 1997;82(2):531–5.
Reiter EO, Lovinger RD. The use of a commercially available somatomedin-C radioimmunoassay in patients with disorders of growth. J Pediatr. 1981;99(5):720–4.
Martin JL, Baxter RC. Insulin-like growth factor-binding protein from human plasma. Purification and characterization. J Biol Chem. 1986;261(19):8754–60.
Blum WF, et al. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab. 1990;70(5):1292–8.
Hasegawa Y, et al. Usefulness and limitation of measurement of insulin-like growth factor binding protein-3 (IGFBP-3) for diagnosis of growth hormone deficiency. Endocrinol Jpn. 1992;39(6):585–91.
Sklar C, et al. Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000;85(9):3227–32.
Cianfarani S, et al. Height velocity and IGF-I assessment in the diagnosis of childhood onset GH insufficiency: do we still need a second GH stimulation test? Clin Endocrinol. 2002;57(2):161–7.
Shalet SM, et al. The diagnosis of growth hormone deficiency in children and adults. Endocr Rev. 1998;19(2):203–23.
Fass B, Lippe BM, Kaplan SA. Relative usefulness of three growth hormone stimulation screening tests. Am J Dis Child. 1979;133(9):931–3.
Penny R, Blizzard RM, Davis WT. Sequential arginine and insulin tolerance tests on the same day. J Clin Endocrinol Metab. 1969;29(11):1499–501.
Loche S, et al. Results of early reevaluation of growth hormone secretion in short children with apparent growth hormone deficiency. J Pediatr. 2002;140(4):445–9.
Maghnie M, et al. Growth hormone (GH) deficiency (GHD) of childhood onset: reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults. J Clin Endocrinol Metab. 1999;84(4):1324–8.
Secco A, et al. Reassessment of the growth hormone status in young adults with childhood-onset growth hormone deficiency: reappraisal of insulin tolerance testing. J Clin Endocrinol Metab. 2009;94(11):4195–204.
Carel JC, et al. Growth hormone testing for the diagnosis of growth hormone deficiency in childhood: a population register-based study. J Clin Endocrinol Metab. 1997;82(7):2117–21.
Popii V, Baumann G. Laboratory measurement of growth hormone. Clin Chim Acta. 2004;350(1–2):1–16.
Grimberg A, Kutikov JK, Cucchiara AJ. Sex differences in patients referred for evaluation of poor growth. J Pediatr. 2005;146(2):212–6.
Deller JJ Jr, et al. Growth hormone response patterns to sex hormone administration in growth retardation. Am J Med Sci. 1970;259(4):292–7.
Martin LG, Clark JW, Connor TB. Growth hormone secretion enhanced by androgens. J Clin Endocrinol Metab. 1968;28(3):425–8.
Grimberg A, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016;86(6):361–97.
Wetterau LA. The pros and cons of sex steroid priming in growth hormone stimulation testing. J Pediatr Endocrinol Metab. 2012;25(11–12):1049–55.
Marin G, et al. The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys. J Clin Endocrinol Metab. 1994;79(2):537–41.
Stanley TL, et al. Effect of body mass index on peak growth hormone response to provocative testing in children with short stature. J Clin Endocrinol Metab. 2009;94(12):4875–81.
Argente J, et al. Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in prepubertal children with exogenous obesity: effect of short- and long-term weight reduction. J Clin Endocrinol Metab. 1997;82(7):2076–83.
Zadik Z, et al. Reproducibility of growth hormone testing procedures: a comparison between 24-hour integrated concentration and pharmacological stimulation. J Clin Endocrinol Metab. 1990;71(5):1127–30.
Bercu BB, et al. Growth hormone (GH) provocative testing frequently does not reflect endogenous GH secretion. J Clin Endocrinol Metab. 1986;63(3):709–16.
Spiliotis BE, et al. Growth hormone neurosecretory dysfunction. A treatable cause of short stature. JAMA. 1984;251(17):2223–30.
Rose SR, et al. The advantage of measuring stimulated as compared with spontaneous growth hormone levels in the diagnosis of growth hormone deficiency. N Engl J Med. 1988;319:201–7.
Lanes R. Diagnostic limitations of spontaneous growth hormone measurements in normally growing prepubertal children. Am J Dis Child. 1989;143(11):1284–6.
Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist, vol. 2. Stanford: Stanford University Press; 1959.
Tanner JM, et al. Assessment of skeletal maturity and prediction of adult height (TW2 method). New York: Academic Press; 1975.
Vogiatzi MG, Copeland KC. The short child. Pediatr Rev. 1998;19(3):92–9.
Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952;40(4):423–41.
Shulman DI, Bercu BB. Abstract 1079: predicted heights in children with growth retardation and bone age delay following 1 to 3 years of growth hormone therapy. In 72nd Annual Meeting of the Endocrine Society, 1990.
Roche AF, Wainer H, Thissen D. The RWT method for the prediction of adult stature. Pediatrics. 1975;56(6):1027–33.
Khamis HJ, Roche AF. Predicting adult stature without using skeletal age: the Khamis-Roche method. Pediatrics. 1994;94(4 Pt 1):504–7.
Topor LS, et al. Variation in methods of predicting adult height for children with idiopathic short stature. Pediatrics. 2010;126(5):938–44.
Hamilton J, Blaser S, Daneman D. MR imaging in idiopathic growth hormone deficiency. AJNR Am J Neuroradiol. 1998;19(9):1609–15.
Ranke MB, Lindberg A. Predicting growth in response to growth hormone treatment. Growth Hormon IGF Res. 2009;19(1):1–11.
Ranke MB, et al. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab. 1999;84(4):1174–83.
Kristrom B, et al. Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature. J Clin Endocrinol Metab. 2009;94(2):483–90.
Cohen P, et al. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab. 2007;92(7):2480–6.
Bakker B, et al. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J Clin Endocrinol Metab. 2008;93(2):352–7.
Ranke MB, Lindberg A. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab. 2010;95(3):1229–37.
Blethen SL, et al. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J Clin Endocrinol Metab. 1996;81(5):1704–10.
Wassenaar MJ, et al. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2009;94(10):3721–30.
Kaufman FR, Sy JP. Regular monitoring of bone age is useful in children treated with growth hormone. Pediatrics. 1999;104(4 Pt 2):1039–42.
Wilson DM. Regular monitoring of bone age is not useful in children treated with growth hormone. Pediatrics. 1999;104(4 Pt 2):1036–9.
Crock PA, et al. Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand. Acta Paediatr. 1998;87(4):381–6.
Darendeliler F, Karagiannis G, Wilton P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res. 2007;68(Suppl 5):41–7.
Bell J, et al. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95(1):167–77.
Allen DB, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol. 2016;174(2):P1–9.
Holly JM, Gunnell DJ, Davey Smith G. Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer? J Endocrinol. 1999;162(3):321–30.
Wilton P. Adverse events during GH treatment: 10 years’ experience in KIGS, a pharmacoepidemiological survey. In: Ranke MB, Wilton P, editors. Growth hormone therapy in KIGS – 10 years’ experience. Heidelberg: Johann Ambrosius Barth Verlag; 1999. p. 349–64.
Moshang T Jr, et al. Brain tumor recurrence in children treated with growth hormone: the National Cooperative Growth Study experience. J Pediatr. 1996;128(5 Pt 2):S4–7.
Ergun-Longmire B, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab. 2006;91(9):3494–8.
Wyatt D. Melanocytic nevi in children treated with growth hormone. Pediatrics. 1999;104(4 Pt 2):1045–50.
Carel JC, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab. 2012;97(2):416–25.
Poidvin A, et al. Growth hormone treatment for childhood short stature and risk of stroke in early adulthood. Neurology. 2014;83(9):780–6.
Savendahl L, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab. 2012;97(2):E213–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Soto-Rivera, C.L., Romero, C.J., Cohen, L.E. (2018). Childhood Growth Hormone Deficiency and Hypopituitarism. In: Radovick, S., Misra, M. (eds) Pediatric Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-73782-9_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-73782-9_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-73781-2
Online ISBN: 978-3-319-73782-9
eBook Packages: MedicineMedicine (R0)